George D. Yancopoulos, M.D., Ph.D., is a distinguished figure in the field of biotechnology, currently serving as the Board co-Chair, President, and Chief Scientific Officer at Regeneron Pharmaceuticals, Inc. Born in 1959, Yancopoulos earned his B.A. in biology from Columbia University and subsequently obtained both his M.D. and Ph.D. from Columbia University's College of Physicians and Surgeons. His early career was marked by a stint as a research fellow at Columbia University, where he worked under the guidance of renowned neuroscientist Dr. Richard Axel. This period laid the groundwork for his future contributions to medical science, particularly in the areas of neurobiology and immunology. At Regeneron, which he joined in 1989 as its founding Chief Scientific Officer, Yancopoulos has been instrumental in steering the company towards groundbreaking advancements in drug development. Under his leadership, Regeneron has developed several blockbuster drugs, including EYLEA for the treatment of wet age-related macular degeneration and ZALTRAP for metastatic colorectal cancer. One of his most notable achievements came during the COVID-19 pandemic when he led the development of REGEN-COV, a monoclonal antibody cocktail that received Emergency Use Authorization from the FDA. His strategic vision and scientific acumen have not only propelled Regeneron to the forefront of the pharmaceutical industry but have also earned him numerous accolades, including the 2014 Ernst & Young New York Entrepreneur of the Year Award and the 2014 National Academy of Sciences Award for Scientific Discovery. In his current role as Board co-Chair, President, and Chief Scientific Officer, Yancopoulos continues to drive Regeneron's scientific and business strategies, overseeing a robust pipeline of innovative therapies. His dual focus on scientific excellence and commercial success has been pivotal in establishing Regeneron as a leader in the development of novel medicines. Beyond his corporate responsibilities, Yancopoulos is also deeply committed to mentoring the next generation of scientists, frequently engaging with academic institutions and contributing to scientific literature. His multifaceted contributions to medicine and biotechnology underscore his status as a visionary leader in the field.